A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Public ClinicalTrials.gov record NCT07109726. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Study identification
- NCT ID
- NCT07109726
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Terremoto Biosciences Inc.
- Industry
- Enrollment
- 205 participants
Conditions and interventions
Conditions
Interventions
- Fulvestrant injection Drug
- TER-2013 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 22, 2025
- Primary completion
- Dec 29, 2028
- Completion
- Feb 27, 2029
- Last update posted
- Mar 22, 2026
2025 – 2029
United States locations
- U.S. sites
- 14
- U.S. states
- 12
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Florida Cancer Specialists - Lake Nona | Orlando | Florida | 32827 | Recruiting |
| Massachusetts General Hospital | Boston | Massachusetts | 02144 | Recruiting |
| Mayo Rochester | Rochester | Minnesota | 55905 | Not yet recruiting |
| Washington Univ. School of Medicine | St Louis | Missouri | 63110 | Recruiting |
| Nebraska Cancer Specialists | Omaha | Nebraska | 68130 | Recruiting |
| Carolina BioOncology Institute | Huntersville | North Carolina | 28078 | Recruiting |
| UH Cleveland Medical Center | Cleveland | Ohio | 44106 | Recruiting |
| Sarah Cannon Nashville | Nashville | Tennessee | 37203 | Recruiting |
| NEXT Oncology | Austin | Texas | 78229 | Recruiting |
| MD Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
| START Center for Cancer Research | San Antonio | Texas | 78229 | Recruiting |
| START Center for Cancer Research | West Valley City | Utah | 84119 | Recruiting |
| NEXT Oncology | Fairfax | Virginia | 22031 | Recruiting |
| Froedtert & MCW Cancer Center | Milwaukee | Wisconsin | 53226 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07109726, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 22, 2026 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07109726 live on ClinicalTrials.gov.